Site models that meet patient needs at the site level.
The overriding theme in clinical development is “get medicines to the patients faster”-and to that end, many different ideas are in the mix. One of the most significant is this evolution around the patient. To get approved medicines to patients in a clinical trial, you have to find the right patients. Many of the new solutions evolving to meet this need address patients at the site level.
At the DIA Annual Meeting in June, Christian Burns, vice president of BTC Network and ClinEdge; Sean Stanton, president and CEO at LifeCore Solutions; and Jennifer Byrne, co-founder and CEO of the newly launched Javara (see: https://bit.ly/2PzGRmE) presented “Rebuilding or Building a Research Site in the Year 2020.” During the session, they presented five site models and led the audience through an interactive discussion on how each of these are evolving to meet specific challenges. The models include virtual sites; specialty practice with research extension; dedicated research sites; large multi-physician health systems with research embedded;
and academic sites. The audience discussed the pain points around each model as follows:
Specialty practice pain points
Large multi-physician practices pain points
Dedicated research site pain points
Due to the compelling topic and interest, the session didn’t have time to delve into the virtual or academic space pain points. In the table above, SCORR Marketing, our market research survey partner, and Applied Clinical Trials wanted to focus on up-and-coming organizations that are driving innovation in each of the site models. Because of space constraints, we chose one for each, but, of course, we will continue to feature these innovators in upcoming articles in our pages and online.
- Staff report
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
FOCUS Trial Results Show Solriamfetol Significantly Reduces ADHD Symptoms, Severity in Adults
March 27th 2025Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention-deficit hyperactivity disorder symptoms and disease severity in adults compared to placebo, with a favorable safety and tolerability profile.